Rare disease news

FDA approvals, research breakthroughs, clinical trials, and advocacy updates

Curated and summarized by AI for patients and caregivers

🔍
AllDrug approvalsClinical trialsResearchGrants & fundingAdvocacy & policyPipeline
Show:All newsBreaking onlyImportant & breaking
Date:7 days30 days90 daysAll time

2 articles matching "hemophilia A"

Drug approvalRSS4 days ago

Data show hemophilia bleeds can be successfully treated while on Hympavzi

Hympavzi is a new injection medicine approved in 2024 to help prevent bleeding in people with hemophilia. In the large study that led to its approval, the medicine worked well at stopping bleeds before they happened. When breakthrough bleeds did occur, doctors were able to treat them successfully using standard blood clotting medicines.

WHY IT MATTERSIf you have hemophilia, this news shows that Hympavzi can reduce bleeding episodes while still allowing doctors to treat any bleeds that do happen with familiar, proven treatments—meaning you don't have to choose between prevention and effective emergency care.
💬 Ask your doctorHemophilia AHemophilia B
🔴 BreakingDrug approvalRSSMay 15

Hympavzi now approved for more hemophilia patients in Europe

Hympavzi, a new hemophilia treatment made by Pfizer, has been approved in Europe for more patients. The drug helps people with hemophilia A or B who have developed inhibitors—a complication where the body fights back against standard treatments. This approval expands who can use the medicine to help them bleed less and stay healthier.

WHY IT MATTERSEuropean hemophilia patients with inhibitors now have access to Hympavzi, a subcutaneous therapy that may reduce bleeding episodes and improve quality of life compared to traditional intravenous treatments.
→ You can act on thishemophilia Ahemophilia B

Get personalized rare disease news

Follow your conditions to see news about the diseases that matter to you — FDA approvals, trial openings, and research breakthroughs.

Create free account →Browse diseases